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Plasma Fibulin-1 Is Linked to Restrictive Filling of the Left Ventricle
and to Mortality in Patients With Aortic Valve Stenosis
Jordi S. Dahl, MD, PhD; Jacob E. Møller, MD, PhD, DMSc; Lars Videbæk, MD, PhD; Mikael K. Poulsen, MD, PhD; Torsten R. Rudbæk, MD;
Patricia A. Pellikka, MD, FACC; W. Scott Argraves, PhD; Lars Melholt Rasmussen, MD, DMSc
Background-—Plasma ﬁbulin-1 levels have been associated with N-terminal pro–B-type natriuretic peptide levels and left atrial size
and shown to be predictive of mortality in patients with diabetes. The mechanisms behind these connections are not fully
understood but are probably related to its roles as an extracellular matrix protein in cardiovascular tissues.
Methods and Results-—One hundred twenty-ﬁve patients with severe aortic stenosis who were scheduled for aortic valve
replacement (AVR) were evaluated with preoperative echocardiography and their plasma ﬁbulin-1 levels were determined with
ELISA. The cohort was followed for a median of 4 years after AVR. Increased restrictive left ventricular (LV) ﬁlling pattern was
observed with increased plasma ﬁbulin-1 levels (2% versus 29% versus 24% in low, middle, and high plasma ﬁbulin-1 tertile groups,
P=0.004). Likewise, reduced longitudinal systolic LV function (6.61.1 versus 6.11.3 versus 5.71.5 cm/s, P=0.05) and
increased LV ﬁlling pressures was systolic velocity of the mitral annulus observed with increasing plasma ﬁbulin-1 concentrations
(ratio of early transmitral ﬂow velocity to early diastolic ﬂow velocity of the mitral annulus 134 versus 155 versus 166 in the
ﬁbulin-1 tertile groups, P=0.04).
Conclusions-—In patients with symptomatic severe aortic stenosis undergoing AVR, plasma ﬁbulin-1 is associated with restrictive
ﬁlling of the LV, decreased longitudinal systolic function of the LV, and increased LV ﬁlling pressures.
Clinical Trial Registration-—URL: www.clinicaltrial.gov with Identiﬁer: NCT00294775 ( J Am Heart Assoc. 2012;1:e003889 doi:
10.1161/JAHA.112.003889)
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T he cardiac consequences of aortic valve stenosis (AS)are characterized by chronic left ventricular (LV)
pressure overload leading to LV hypertrophy and myocardial
ﬁbrosis, with both increasing myocardial stiffness. The
consequence of increased myocardial stiffness is diastolic
dysfunction, increased LV ﬁlling pressures, left atrial (LA)
dilatation, shortness of breath, and increased risk of atrial
ﬁbrillation (AF).1–4 Increased myocardial stiffness may addi-
tionally prevent the remission of heart failure symptoms after
aortic valve surgery3,4 worsening postoperative outcome.4
Markers of myocardial stiffness are thus warranted. A
restrictive LV ﬁlling pattern assessed by echocardiography
may identify patients with increased myocardial stiffness.
Because LV ﬁlling pattern, however, also is affected by loading
conditions and LV relaxation, increased myocardial stiffness
may be present despite a nonrestrictive ﬁlling pattern.
Fibulin-1 is an extracellular matrix (ECM) and blood protein
emerging as a biomarker in several cardiovascular dis-
eases.5,6 During development, it is expressed in endocardial
cushions, cardiac valves, and myocardium.7–9 In adults, it is
also a prominent ECM component of cardiac valves, heart
muscle, and blood vessels.5,10 We recently demonstrated an
association between plasma ﬁbulin-1 levels and the presence
of cardiovascular disease and showed that it is predictive for
all-cause and cardiovascular mortality in patients with diabe-
tes.5 Fibulin-1 is upregulated in cardiomyopathy,11 and
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ﬁbulin-1 blood levels are positively associated with plasma
N-terminal pro–B-type natriuretic peptide (NT-proBNP) levels
and LA size.5,6 In the present investigation, we evaluated the
hypothesis that plasma ﬁbulin-1 may be associated with LV
diastolic impairment and increased LV ﬁlling pressures, which
result in a poorer postoperative outcome in patients with AS.
Methods
The present investigation is a substudy of a prospective
single-center, randomized study to evaluate the effect of
candesartan compared with conventional treatment on
reverse remodeling in consecutive patients undergoing aortic
valve replacement (AVR) for symptomatic AS. The study was
registered with the National Board of Health and the Danish
Data Protection Agency (ClinicalTrials.gov Identiﬁer:
NCT00294775) and was approved by the local ethical
committee, and all patients gave written informed consent.
The study design and effect of candesartan on regression of
LV hypertrophy have previously been published.12 In brief,
patients aged >18 years with symptomatic severe AS (esti-
mated aortic valve area <1 cm2) scheduled for AVR at Odense
University Hospital, Odense, Denmark, during February 2006
to April 2008 were enrolled. Patients with LV ejection fraction
<40%, serum creatinine >220 lmol/L, previous aortic valve
surgery, planned additional valve repair/replacement, infec-
tive endocarditis, predominant aortic valve regurgitation, or
ongoing treatment with an angiotensin-converting enzyme
inhibitor or an angiotensin receptor blocker were excluded. All
patients undergoing AVR were enrolled in this study and
divided among 3 groups according to ﬁbulin-1 tertile.
Echocardiography
All echocardiograms were performed by the same operator
with a GE Vivid 5 ultrasound machine (GE Medical System,
Horten, Norway) the day before surgery and were repeated
12 months after AVR. Echocardiograms were digitally stored
and later analyzed in a blinded manner for all clinical data,
survival data, and ﬁbulin-1 levels. Aortic valve area was
estimated with quantitative Doppler using the continuity
equation. Peak ﬂow velocity across the valve was determined
in the window where the highest velocity could be recorded
using continuous-wave Doppler with the cursor as parallel as
possible with the ﬂow across the valve. Peak transvalvular
gradient was estimated using the modiﬁed Bernoulli equation.
Finally, the peak systolic ﬂow velocity in the outﬂow tract was
estimated with pulsed-wave Doppler.13
As a measure of LV hypertrophy, LV mass was estimated
according to the joint recommendations of the American
Society of Echocardiography and European Association of
Echocardiography using the Devereux formula: 0.89(1.04 [LV
internal diameter+posterior wall thickness+interventricular
septal thickness]3  [LV internal diameter]3)+0.6 g. Diastolic
LV wall thickness and dimensions were estimated from the
average of 3 consecutive frozen 2-dimensional images
obtained in the parasternal long axis.14 In men and women,
LV mass index (LVMi) >116 g/m2 and >100 g/m2, respec-
tively, was considered indicative of LV hypertrophy.15 Relative
wall thickness was calculated using the formula 29posterior
wall thickness/LV internal diameter in diastole.16
LV ejection fraction was estimated using the Simpson
biplane method. Longitudinal LV systolic function was
assessed using peak systolic mitral annular motion assessed
with tissue Doppler imaging with the Doppler sample volume
placed in the septal and lateral mitral valve annulus.
Mitral inﬂow was assessed in the apical 4-chamber view
using pulsed-wave Doppler with the sample volume paced at
the tips of mitral leaﬂets during diastole. From the mitral
inﬂow proﬁle, the E- and A-wave peak velocities and
deceleration time were measured. Doppler tissue imaging
of the mitral annulus was used in the aforementioned
sampling sites to measure the early diastolic e′ velocity from
each site. The ratio of early transmitral ﬂow velocity to early
diastolic ﬂow velocity of the mitral annulus (E/e′ ratio) was
used as a noninvasive marker of LV ﬁlling pressures.17 The
diastolic and restrictive ﬁlling patterns were categorized
according to European Association of Echocardiography
guidelines.18
LA volume was assessed using the area–length method15
from the apical 4- and 2-chamber views. Measurements were
obtained in end-systole from the frame preceding mitral valve
opening, and the volume was indexed for body surface area.
Biochemical Analysis
Blood samples were collected immediately after the echocar-
diogram, after the subject had been resting recumbent for at
least 30 minutes. Samples were collected in EDTA-containing
tubes. The tubes were then centrifuged, and plasma samples
were stored at 80°C for later analysis. A sandwich
immunoassay for ﬁbulin-1 was used for measuring ﬁbulin-1
levels.5,19 NT-proBNP and creatinine levels were analyzed with
a Modular Analytics P device (Roche Diagnostics, Indianapolis,
IN, USA).
Assessment of Atrial Fibrillation
Patients were examined 1, 3, 6, 9, and 12 months after AVR
and underwent a 12-lead resting ECG for 2 minutes in the
supine position. In addition, a 24-hour Holter electrocardio-
graphic recording was performed 3 months after surgery, and
a 48-hour Holter was performed at 12 months. These
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recordings were performed with a Reynolds Medical Tracker 3
and a Pathﬁnder 700 (Reynolds Medical Limited, England) for
analysis. All ECGs were interpreted by the same experienced
cardiologist, who was blinded to treatment allocation and
ﬁbulin-1 levels. An episode of irregular heart rhythm with no
deﬁnite p waves and with a duration >30 seconds was
considered to be AF according to guidelines.20 Episodes of AF
occurring within 30 days of AVR were considered to be
postoperative AF and were not recorded as an end point.
Patients with known AF before AVR were excluded in
analyses estimating the association of ﬁbulin-1 with the
development of AF.
Clinical Examination and Follow-up
All patients had coronary angiography performed before AVR
and underwent a thorough clinical examination on the day
before AVR. Arteriosclerosis was deﬁned as previous history
of cerebral stroke, aortic disease, peripheral arterial disease,
or coronary heart disease or if arteriosclerosis was present on
the preoperative coronary angiogram. In addition operative
risk was estimated using the European System for Cardiac
Operative Risk Evaluation (EuroSCORE).21
By July 2011, data on outcomes were collected from the
Danish Personnel Register (survival status) and from dis-
charge notes available in the Danish admission registry. In
case of ambiguous information, local hospitals were con-
tacted and detailed patient charts were reviewed.
The main end point for this study was cardiovascular
mortality; the secondary end point was AF.
Statistics
Data are presented as meanSD or number and percentages.
Differences between groups were tested by ANOVA; categor-
ical variables were tested by Fisher exact test. Due to a
nongaussian distribution, NT-proBNP was logarithm trans-
formed. The association of ﬁbulin-1 with arteriosclerosis and
restrictive ﬁlling was tested by multivariate ANOVA. Mortality
and event rates were calculated using the product–limit
method and plotted according to the Kaplan–Meier method;
death rates were compared using the log-rank test. Further
estimation of risk was performed using Cox proportional
hazard models. In addition to hazard ratios, adjusted hazard
ratios for 1 SD were calculated, dividing the variable by the SD
of the measure. We used DAGitty, a web-based application
based on the directed acyclic graph theory, to model the
causal relationship between ﬁbulin-1 and cardiovascular
mortality and any confounders.22 This DAG program was
used to identify sets of confounders that together fully adjust
for confounding in multivariable modeling.23 Several of these
sets of confounders were identiﬁed (Figure S1). The set
containing age, history of diabetes, AS severity, and LVMi was
used for multivariable analysis.
The assumptions (proportional hazard assumption, linearity
of continuous variables, and lack of interaction) were tested
and found to be valid.
A P value <0.05 was considered signiﬁcant. STATA/SE 9.0
(StataCorp LP, College Station, TX, USA) software was used
for statistical analysis.
Results
Table 1 provides baseline clinical data for 125 patients
stratiﬁed according to plasma ﬁbulin-1 level, which was
8933 lg/mL in the complete cohort. Fibulin-1 level was
579 lg/mL in the ﬁrst tertile, 859 lg/mL in the second
tertile, and 12527 lg/mL in the third tertile. Age and
history of diabetes, coronary heart disease, peripheral artery
disease, AF, and stroke were similar between groups. There
was a predominance of women in the 2 upper tertiles (19%
versus 48% versus 54%, P=0.01). There was a trend toward an
increased EuroSCORE result in patients with increased
plasma ﬁbulin-1 levels (5.31.9 versus 5.91.8 versus
6.12.1, respectively; P=0.13).
AVR was performed in all patients. Coronary artery bypass
grafting was performed in 37 (30%) patients with no difference
between groups (Table 1); complete revascularization was
achieved in all patients. No difference in the size or type of
aortic valve prosthesis was seen between groups; additionally,
the use of b-blockers, calcium-channel blockers, angiotensin-
converting enzyme inhibitors, and diuretics was equal
between groups preoperatively. Randomization to candesar-
tan treatment was similar between groups (Table 1). A poor
but signiﬁcant correlation was seen between creatinine and
ﬁbulin-1 levels (r=0.18, P=0.042; data not shown). Creatinine
levels were, however, similar between groups (9821 versus
9719 versus 10524 lmol/L, respectively; P=0.22)
(Table 1). Table 2 shows echocardiographic data distributed
among groups.
A trend toward decreased aortic valve area was seen in
patients with increased plasma ﬁbulin-1 levels (0.90.3
versus 0.70.2 versus 0.80.3 cm2, respectively; P=0.07).
Plasma ﬁbulin-1 correlated positively with indices of LV
hypertrophy (LVMi: r=0.19, P=0.034; interventricular septal
thickness: r=0.21, P=0.02). The presence of LV hypertrophy
was, however, not signiﬁcantly different between groups (64%
versus 67% versus 78%, respectively; P=0.35). Increased
plasma ﬁbulin-1 levels were associated with increased
occurrence of LV restrictive ﬁlling, elevated ﬁlling pressures,
and increased LA volume index (4519 versus 4617 versus
5518 mL/m2, respectively; P=0.04). In addition, plasma
ﬁbulin-1 levels were associated with reduced longitudinal
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systolic LV function measured as s′sep (6.61.1 versus
6.11.3 versus 5.71.5 cm/s, respectively; P=0.05). Plasma
ﬁbulin-1 was increased in patients with LV restrictive ﬁlling
independent of the presence of arteriosclerosis (8731
versus 10026 lg/mL in patients without arteriosclero-
sis and 8434 versus 12335 lg/mL in patients with
arteriosclerosis; multivariate ANOVA Prestrictive ﬁlling=0.009,
Parteriosclerosis=0.94).
LVMi regression during follow-up was not signiﬁcantly
different between groups (1425 versus 2036 versus
3142 g/m2, respectively; P=0.15) (Table 3), although
LVMi was similar between groups (11335 versus 10729
versus 11229 g/m2, respectively; P=NS) at 12 months
after surgery. Although ejection fraction at 12 months after
AVR was similar between groups, s′sep remained reduced in
patients with increased preoperative ﬁbulin-1 levels (7.11.5
versus 6.31.3 versus 6.11.4 cm/s, respectively;
P=0.007).
Atrial Fibrillation
Twenty-nine patients developed AF during the ﬁrst postoper-
ative year: 7 in the ﬁrst group, 9 in the second group, and 13
Table 1. Characteristics of Patients
Fibulin-1
First
Tertile
(n=42)
Fibulin-1
Second
Tertile
(n=42)
Fibulin-1
Third
Tertile
(n=41) P
Age, y 718 7211 748 0.36
Male sex 34 (81) 22 (52) 23 (56) 0.01
Hypertension 22 (52) 15 (36) 16 (39) 0.26
Arteriosclerosis 21 (50) 17 (40) 19 (46) 0.68
Diabetes
mellitus
5 (12) 6 (14) 8 (20) 0.62
AF 4 (5) 5 (12) 10 (24) 0.13
Ischemic
heart
disease
9 (21) 7 (17) 7 (17) 0.82
Peripheral
artery
disease
5 (12) 2 (5) 4 (10) 0.50
Stroke 1 (2) 3 (7) 4 (10) 0.38
EuroSCORE 5.31.9 5.91.8 6.12.1 0.13
Logistic
EuroSCORE
4.63.1 5.63.3 6.35.3 0.16
Diuretic therapy 17 (40) 11 (26) 16 (39) 0.32
b-Blocker
therapy
8 (19) 9 (21) 11 (27) 0.69
CCB therapy 11 (26) 7 (17) 7 (17) 0.47
Candesartan 19 (45) 21 (50) 23 (56) 0.61
Symptoms
6-min walk
test, m
348126 338123 347128 0.94
NYHA
functional
class
2.20.7 2.00.7 2.10.7 0.30
NYHA
functional
class 1/2/3/4
6/20/16/0 9/24/9/0 8/21/11/1 0.52
Creatinine,
lmol/L
9821 9719 10524 0.22
Plasma ﬁbulin-1,
lg/mL
579 859 12527
Data are n (%) or meanSD or n. AF indicates atrial ﬁbrillation; CCB, calcium channel
blocker; NYHA, New York Heart Association.
Table 2. Preoperative Echocardiographic Data
Fibulin-1
First
Tertile
(n=42)
Fibulin-1
Second
Tertile
(n=42)
Fibulin-1
Third
Tertile
(n=41) P
AVA, cm2 0.90.3 0.70.2 0.80.3 0.07
AV velocity,
m/s
3.70.7 4.00.7 4.00.9 0.17
LVMi, g/m2 12132 12841 14445 0.03
IVS, mm 122 132 143 0.002
LV posterior
wall thickness,
mm
132 132 142 0.11
LV hypertrophy 27 (64) 28 (67) 32 (78) 0.35
LAVi, mL/m2 4519 4617 5518 0.04
LVEDD, mm 466 447 456 0.31
Mitral E velocity,
m/s
0.70.2 0.80.2 0.80.3 0.14
Mitral A velocity,
m/s
1.00.3 0.90.3 1.00.3 0.37
Mitral DT, ms 21960 18552 19059 0.01
Restrictive
ﬁlling pattern
1 (2) 12 (29) 10 (24) 0.004
Diastolic function
0/1/2/3 2/22/17/1 1/9/20/12 3/14/13/10 0.02
e′sep, cm/s 5.71.5 5.91.8 5.71.7 0.92
E/e′sep 134 155 166 0.04
Systolic function
EF, % 547 549 556 0.91
S′sep, cm/s 6.61.1 6.11.3 5.71.5 0.05
log NTproBNP 5.81.1 6.21.4 6.71.3 0.008
Data are n (%) or meanSD or n. AVA indicates aortic valve area; AV, aortic valve; IVS,
interventricular septal thickness; LAVi, left atrial volume index; LVEDD, left ventricular
end diastolic diameter; DT, deceleration time; EF, ejection fraction; NT-proBNP,
N-terminal pro–B-type natriuretic peptide; E'sep, early diastolic velocity of the septal
mitral annulus; S'sep, systolic velocity of the septal mitral annulus.
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in the third group. In a univariable Cox regression model,
plasma ﬁbulin-1, LA volume index, age, plasma NT-proBNP,
and LVMi were associated with the development of AF. After
adjustment for age and LAVi, only plasma ﬁbulin-1 remained
signiﬁcantly associated with AF development (Table 4).
Clinical Outcome
The mean follow-up duration after AVR in the total cohort was
3.81.5 years (median 4.0 years). Survival status was
available for all patients. Overall, there were 29 deaths: 8 in
the ﬁrst tertile, 8 in the second tertile, and 13 in the third
tertile. The cause of 4 deaths was not a cardiac condition
(n=2, cancer; n=1, infectious disease; n=1, subarachnoid
hemorrhage), and 25 patients had a cardiac cause of death
(n=15, sudden cardiac death; n=7, postoperative death; n=2,
congestive heart failure; n=1, aortic aneurysm).
Overall mortality and cardiac mortality were signiﬁcantly
increased in patients with increased plasma ﬁbulin-1 levels
(estimated 5-year cardiac mortality rate: ﬁrst tertile 13%
[n=5], second tertile 17% [n=7], third tertile 32% [n=13],
P=0.04, Figure 1).
In a univariable Cox regression analysis, ﬁbulin-1, LA
volume index, LVMi, and s′sep were associated with cardiac
survival (Table 5). No effect modiﬁcation was demonstrated
by sex, age, LA volume, LVMI, or diabetes on the association
between ﬁbulin-1 and cardiovascular mortality.
In a multivariable Cox model including the predeﬁned
variables of age, LA volume, and diabetes, only ﬁbulin-1 and a
history of diabetes mellitus were associated with cardiac
mortality (Table 5).
Discussion
The main ﬁnding in our study is that increased levels of
plasma ﬁbulin-1 associate with restrictive LV ﬁlling and
increased LV ﬁlling pressures in patients with AS. Second,
plasma ﬁbulin-1 appeared to be associated with the develop-
ment of AF and long-term postoperative cardiovascular
mortality when adjusted for other factors in the study
patients. These observations add to the emerging evidence
that plasma ﬁbulin-1 levels are reﬂective of cardiovascular
disease, including ﬁndings showing that plasma ﬁbulin-1
levels are associated with LA size and blood levels of NT-
proBNP5 in patients with diabetes mellitus.
Fibulin-1 is an ECM protein24,25 prominently expressed
during the development in endocardial cushions, cardiac
valves, outﬂow track, blood vessels, and the ventricular
myocardium. Indeed, mice deﬁcient in ﬁbulin-1 develop
outﬂow tract and ventricular myocardial abnormalities and
defects in peripheral blood vessels that are associated with
hemorrhage.9,26 Fibulin-1 is also a prominent constituent of
the cardiovascular system, where it is expressed in cardiac
valves, cardiac muscle, and blood vessels, including the aorta
Table 3. Echocardiographic Data 12 Months After AVR
Fibulin-1
First
Tertile
(n=35)
Fibulin-1
Second
Tertile
(n=35)
Fibulin-1
Third
Tertile
(n=33) P
LVMi, g/m2 11335 10729 11229 0.72
IVS (mm) 123 122 122 0.91
LV posterior
wall
thickness,
mm
122 122 122 0.39
LAVi,
mL/m2
4716 4214 5218 0.04
LVEDD,
mm
456 446 455 0.75
Mitral E
velocity,
m/s
0.90.3 0.90.3 0.90.3 0.93
Mitral A
velocity,
m/s
1.00.2 0.90.2 1.00.3 0.24
Mitral DT,
ms
21845 19861 18354 0.04
e′sep, cm/s 6.31.6 6.11.4 5.91.9 0.65
E/e′sep 157 157 178 0.71
Systolic function
EF (%) 537 517 549 0.38
S′sep
(cm/s)
7.11.5 6.21.3 6.11.4 0.007
log NT-
proBNP
5.91.2 5.81.1 6.11.0 0.51
Plasma
ﬁbulin-1,
lg/mL
6313 8917 12133 <0.001
Difference during
follow-up
LVMi,
g/m2
1425 2036 3142 0.15
EF, % 17 211 111 0.88
S′sep, cm/s 1.01.2 0.41.6 0.61.5 0.31
LAVi, mL/m2 0.211 3.312 2.414 0.61
Plasma
ﬁbulin-1,
lg/mL
6.611.3 3.819 0.627 0.51
Data are n (%) or meanSD. AVR indicates aortic valve replacement; LVMi, left
ventricular mass index; IVS, interventricular septal thickness; LV, left ventricular; LAVi,
left atrial volume index; LVEDD, left ventricular end diastolic diameter; DT, deceleration
time; EF, ejection fraction; NTproBNP, N-terminal pro–B-type natriuretic peptide E'sep,
early diastolic velocity of the septal mitral annulus; S'sep, systolic velocity of the septal
mitral annulus.
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and coronary and carotid arteries.5,10 Despite extensive
expression of ﬁbulin-1 in cardiovascular tissues, often in
relation to elastin-containing ﬁbers and elastic laminae,5,10
little is known about its function. The idea that ﬁbulin-1 may
reﬂect accumulation of ECM in ﬁbrotic myocardium and
correlations found in the present study ﬁt with a recent
Brazilian study demonstrating that myocardial ﬁbrosis is a
prognostic marker for postoperative outcome.3,4 The main
constituents of the myocardial matrix are type I and, to a
lesser extent, type III collagen. Interestingly, the myocardium
also contains small amounts of elastin, which may play an
important beneﬁcial functional role, particularly in relation to
the preservation of diastolic function.27,28 Whether our
ﬁndings of changes in the elastin-associated matrix molecule
ﬁbulin-1 in relation to restrictive ﬁlling of the LV should be
interpreted in this context remains to be seen.
Fibulin-1 circulates in relatively high concentrations in
plasma5,19; however, the source of ﬁbulin-1 in the blood is not
known. Considering that myocardial ﬁbulin-1 mRNA levels
have been shown to increase in an animal model of
cardiomyopathy11 and in a human model of the arterial wall
in diabetes,5 it is possible that different cardiovascular
pathologic conditions may augment tissue ﬁbulin-1 to be
released into the blood. Because ﬁbulin-1 is expressed in
valves,10 it is possible that ﬁbrotic valves could also
contribute ﬁbulin-1 to the blood.
As stated earlier, our previous study established a link
between plasma ﬁbulin-1 and LA dilatation and plasma NT-
proBNP concentrations in diabetic patients. We suggested
that these associations could be secondary to increased
arterial stiffness, because we observed increased arterial
ﬁbulin-1 concentrations in the arterial ECM in individuals
with type 2 diabetes and because there was a correlation
between plasma ﬁbulin-1 and carotid compliance.5
Increased vessel stiffness could lead to premature return
Table 4. Univariable Predictors of AF
Univariable Univariable*
HR (95% CI) HRprSD P HR HRprSD P
Fibulin-1 1.01 (1.00 to 1.02) 1.49 0.01 1.01 1.41 0.04
Fibulin-1 tertiles
First 1
Second 1.4 (0.5 to 3.8) 0.50
Third 2.2 (0.9 to 5.5) 0.09
LVEF, % 0.99 (0.95 to 1.05) 0.99 0.99
Age, /y 1.06 (1.01 to 1.12) 1.70 0.02
EuroSCORE 1.17 (0.97 to 1.41) 1.36 0.10
Diabetes mellitus 1.00 (0.34 to 2.9) 0.99
LAVi, mL/m2 1.03 (1.01 to 1.05) 1.69 0.001
LVMi, g/m2 1.01 (1.00 to 1.02) 1.46 0.014 1.00 1.03 0.87
E/e′avg 1.04 (0.97 to 1.11) 1.23 0.26
NT-proBNP 1.00 (1.00 to 1.00) 1.42 0.001 1.00 1.19 0.25
LVEDD, cm 1.18 (0.65 to 2.1) 1.11 0.59
S′sep, cm/s 0.81 (0.63 to 1.04) 0.73 0.10 0.69 0.98 0.93
AF indicates atrial ﬁbrillation; HR, hazard ratio; HRprSD, hazard ratio per SD; LVEF, left ventricular ejection fraction; LAVi, left atrial volume index; LVEDD, left ventricular end-diastolic
diameter; NT-proBNP, N-terminal pro–B-type natriuretic peptide; S'sep, systolic velocity of the septal mitral annulus.
*Adjusted for age and LAVi.
Figure 1. Kaplan–Meier plot showing survival free of cardiac death
after AVR on ﬁbulin-1 tertile. LV indicates left ventricular; EF, ejection
fraction; CV, cardiovascular; NT-proBNP, N-terminal pro–B-type
natriuretic peptide; AVR, aortic valve replacement.
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of reﬂected pulse waves in late systole,29,30 causing
abnormal LV relaxation and impaired LV ﬁlling. However,
ﬁlling of the LV is affected by several important myocardial
factors, in addition to myocardial relaxation, atrial pressure,
and LV compliance. AS is often accompanied by LV
remodeling leading to altered LV compliance but is also
associated with arteriosclerosis and arterial stiffness. In the
present study, signiﬁcant differences in ﬁbulin-1 levels
between patients with or without known arteriosclerosis
were not established, but still we ﬁnd associations between
ﬁbulin-1 and measures of restrictive ﬁlling pattern. This
ﬁlling pattern with rapid pressure equalization (reduced
deceleration time) is only seen in the presence of a stiff
myocardium and elevated ﬁlling pressures, as opposed to
impaired relaxation pattern with a long deceleration time,
which is predominant among patients with arterial stiffness.
The observed association between plasma ﬁbulin-1 and
restrictive LV ﬁlling pattern is therefore compatible with the
idea that plasma ﬁbulin-1 directly reﬂects the degree of
myocardial stiffness. Decreased LV compliance and
increased LA pressures will eventually dilate the LA,
increasing the risk of AF. In line with this notion, we ﬁnd
that plasma ﬁbulin-1 levels predict AF when adjusted for LA
size, suggesting an effect not merely related to changes in
hemodynamic parameters. Interestingly, novel ﬁndings of
Garcia et al31 recently demonstrated that ﬁbulin-1 levels are
signiﬁcantly altered in atrial tissue of patients with AF,
although decreased levels were observed in diseased tissue.
It is known that atrial ﬁbrosis is associated with AF
independent of ﬁlling hemodynamics32; it is possible that
ﬁbulin-1 plays a central role in the development of aberrant
ECM in the atrial tissue of individuals with AF. Weidemann
and colleagues recently demonstrated an association
between increased ﬁbrosis assessed by MRI and reduced
longitudinal systolic function measured with tissue Doppler
in AS.3 It is therefore intriguing that we observed reduced s′
velocities in patients with increased ﬁbulin-1 levels, com-
patible with the idea that plasma ﬁbulin-1 could reﬂect
myocardial ﬁbrosis.
Study Limitations
Our sample size is relatively small, with few events, which
makes our models unstable because confounding may be
Table 5. Univariable and Multivariable Predictors of Cardiac Death
Univariable Univariable* Multivariable
HR (95% CI) HRprSD P HR HRprSD P HR HRprSD P
Fibulin-1 1.01 (1.00 to 1.03) 1.62 0.004 1.01 1.56 0.009 1.01 1.41 0.04
Fibulin-1 tertiles
First 1 1
Second 1.44 (0.5 to 4.5) 0.54 1.46 0.53
Third 2.89 (1.0 to 8.1) 0.04 2.69 0.04
LVEF, % 0.97 (0.92 to 1.02) 0.77 0.99 0.97 0.80 0.27
Female sex 1.26 (0.6 to 2.8) 0.58
Age, /y 1.05 (0.99 to 1.10) 1.53 0.07 1.04 1.42 0.15
EuroSCORE 1.20 (0.99 to 1.45) 1.46 0.06
Diabetes 3.2 (1.4 to 7.3) 0.007 3.4 0.005 3.3 0.01
IHD 0.80 (0.3 to 2.3) 0.69 0.82 0.88
Hypertension 0.78 (0.2 to 1.8) 0.54 0.72 0.43
AVA 1.85 (0.5 to 7.1) 1.18 0.37 2.43 1.28 0.20 3.1 1.36 0.07
LAVi 1.02 (1.00 to 1.04) 1.47 0.03 1.02 1.36 0.10
LVMi 1.01 (1.00 to 1.02) 1.40 0.047 1.01 1.29 0.16 1.01 1.37 0.12
E/e′avg 1.07 (1.00 to 1.15) 1.32 0.06 1.05 1.25 0.29
NT-proBNP 1.00 (1.00 to 1.00) 1.11 0.50 1.00 1.04 0.83
LVEDD 0.96 (0.51 to 1.8) 0.95 0.89 0.89 0.93 0.75
S′sep 0.74 (0.56 to 0.98) 0.64 0.04 0.78 0.69 0.11
HR indicates hazard ratio; HRprSD, hazard ratio per SD; LVEF, left ventricular ejection fraction; IHD, ischemic heart disease; AVA, aortic valve area; LAVi, left atrial volume index; LVMi, left
ventricular mass index; LVEDD, left ventricular end-diastolic diameter; NT-proBNP, N-terminal pro–B-type natriuretic peptide.
*Adjusted for sex and age.
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present; the small sample size does not allow control for
potential confounders. Larger studies are therefore war-
ranted. The entry criterion for the study was symptomatic AS
referred for AVR. Future studies should also include asymp-
tomatic patients to clarify whether our ﬁndings apply to a
general population with AS.
LV structure was assessed by echocardiography, and no
histologic examinations were performed; thus, we can only
speculate on the degree of myocardial and valvular pathologic
conditions. No direct hemodynamic measurements of LV end-
diastolic or LA pressure were performed. However, E/e′ is
accepted as a well-validated surrogate in a wide range of
patients with cardiac disease including AS.17
Clinical Implication
The present study demonstrates that preoperative plasma
ﬁbulin-1 levels in patients with AS are associated with
restrictive ﬁlling of the LV, decreased longitudinal systolic
function of the LV, and increased LV ﬁlling pressures.
Moreover, plasma ﬁbulin-1 levels are associated with AF
and long-term postoperative mortality when adjusted for other
factors in these patients. Thus, plasma ﬁbulin-1 may be a new
candidate marker to be used in clinical settings and research
investigations to assess myocardial stiffness.
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